PL2790719T3 - Sposoby zapobiegania lub leczenia pewnych zaburzeń przez hamowanie wiązania IL-4 i/lub IL-13 z ich odpowiednimi receptorami - Google Patents
Sposoby zapobiegania lub leczenia pewnych zaburzeń przez hamowanie wiązania IL-4 i/lub IL-13 z ich odpowiednimi receptoramiInfo
- Publication number
- PL2790719T3 PL2790719T3 PL12813295T PL12813295T PL2790719T3 PL 2790719 T3 PL2790719 T3 PL 2790719T3 PL 12813295 T PL12813295 T PL 12813295T PL 12813295 T PL12813295 T PL 12813295T PL 2790719 T3 PL2790719 T3 PL 2790719T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- methods
- inhibiting binding
- treating certain
- certain disorders
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 | |
| EP12813295.8A EP2790719B1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors. |
| PCT/EP2012/075146 WO2013087660A1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2790719T3 true PL2790719T3 (pl) | 2019-05-31 |
Family
ID=47552959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12813295T PL2790719T3 (pl) | 2011-12-13 | 2012-12-12 | Sposoby zapobiegania lub leczenia pewnych zaburzeń przez hamowanie wiązania IL-4 i/lub IL-13 z ich odpowiednimi receptorami |
| PL18197286T PL3453400T3 (pl) | 2011-12-13 | 2012-12-12 | Sposoby zapobiegania lub leczenia pewnych zaburzeń za pomocą hamowania wiązania IL-4 i/lub IL-13 z ich odpowiednimi receptorami |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18197286T PL3453400T3 (pl) | 2011-12-13 | 2012-12-12 | Sposoby zapobiegania lub leczenia pewnych zaburzeń za pomocą hamowania wiązania IL-4 i/lub IL-13 z ich odpowiednimi receptorami |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (enExample) |
| EP (3) | EP3842058B1 (enExample) |
| JP (5) | JP6163162B2 (enExample) |
| CN (2) | CN109432402B (enExample) |
| AU (1) | AU2012350660B2 (enExample) |
| CA (1) | CA2858962C (enExample) |
| DK (2) | DK2790719T3 (enExample) |
| ES (2) | ES2863410T3 (enExample) |
| HU (2) | HUE042720T2 (enExample) |
| PL (2) | PL2790719T3 (enExample) |
| SG (2) | SG11201402992SA (enExample) |
| TR (1) | TR201901826T4 (enExample) |
| WO (1) | WO2013087660A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201906295T4 (tr) * | 2010-06-08 | 2019-05-21 | Astrazeneca Ab | IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. |
| ES2863410T3 (es) * | 2011-12-13 | 2021-10-11 | Pieris Pharmaceuticals Gmbh | Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores. |
| BR112016027024A2 (pt) | 2014-05-22 | 2017-10-31 | Pieris Pharmaceuticals Gmbh | polipeptídeos de ligação específica e seus usos |
| EP3322433B1 (en) | 2015-07-15 | 2023-05-31 | Pieris Pharmaceuticals GmbH | Novel proteins specific for lag-3 |
| CN107474134B (zh) * | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| EP3571219A1 (en) | 2017-01-18 | 2019-11-27 | Pieris Pharmaceuticals GmbH | Lipocalin muteins with binding affinity for lag-3 |
| AU2018254542B2 (en) * | 2017-04-21 | 2022-12-22 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| CN111514292B (zh) * | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| AU2020253034A1 (en) * | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| KR20210146934A (ko) * | 2019-03-29 | 2021-12-06 | 아스트라제네카 에이비이 | 천식 치료를 위한 리포칼린 뮤테인 |
| PE20240799A1 (es) | 2020-12-18 | 2024-04-18 | Astrazeneca Ab | Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US7238661B2 (en) * | 2002-05-24 | 2007-07-03 | Agennix, Inc. | Oral lactoferrin in the treatment of respiratory disorders |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| JP5608368B2 (ja) * | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | 涙リポカリンの突然変異タンパク質およびそれを得るための方法 |
| JP2010533204A (ja) * | 2007-07-11 | 2010-10-21 | アエロヴァンス インコーポレイティッド | 薬学的ポリペプチドの乾燥粉末エアロゾル製剤およびその調製方法 |
| TR201906295T4 (tr) | 2010-06-08 | 2019-05-21 | Astrazeneca Ab | IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. |
| ES2863410T3 (es) * | 2011-12-13 | 2021-10-11 | Pieris Pharmaceuticals Gmbh | Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores. |
-
2012
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 US US14/364,449 patent/US9572863B2/en not_active Expired - Fee Related
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en not_active Ceased
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja not_active Expired - Fee Related
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh not_active Expired - Fee Related
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en not_active Ceased
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh not_active Expired - Fee Related
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja not_active Expired - Fee Related
- 2019-07-16 US US16/513,636 patent/US10857202B2/en not_active Expired - Fee Related
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311262B2 (en) | Methods for treating or preventing cholesterol-related disorders | |
| HUE042720T2 (hu) | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén | |
| IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| ZA201606957B (en) | Biguanide compositions and methods of treating metabolic disorders | |
| ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
| IL229257A0 (en) | Preparations and methods for the treatment of diseases related to the retina of the eye | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| EP2675460A4 (en) | TREATMENT OF FAT TISSUE UNDER CHIN | |
| IL232710A0 (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
| IL231151A0 (en) | Method and preparation for treating lice | |
| IL230433A0 (en) | Pain management methods | |
| IL232190A0 (en) | A method for treating inflammatory diseases by anti-m-csf antibodies | |
| EP2747768A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| IL231157A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
| AP2013007056A0 (en) | Methods and compositions for treating kidney disorders | |
| EP2919856A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS | |
| ZA201309109B (en) | Methods of treating biomass | |
| IL227703A0 (en) | Converted Ometic Sulfur Compounds and Methods of Using Them | |
| GB201116335D0 (en) | A method of treating or preventing affective disorders | |
| GB201119458D0 (en) | Compositions for treatment of sleep disorders | |
| GB201101183D0 (en) | Treatment of neurodegenerative disorders | |
| GB201101773D0 (en) | Treatment of inflammatory disorders | |
| GB201118065D0 (en) | Treatment of movement disorders |